Mochi and Ivím both describe continuing access to healthcare professionals rather than a medicine-only sale. Their membership descriptions can help explain what ongoing care means, but neither should be compared solely by a low medication advertisement or a large outcome headline.
Their evidence presentations also differ. Mochi qualifies its displayed first-year result as member self-report, while Ivím describes published retrospective observational studies. Those are useful distinctions, not a way to declare one service more effective from incompatible public figures.
The membership is only part of the total
Mochi’s current monthly membership description advertises $39 for the first month for eligible new subscribers and $79 afterward. Its qualification explicitly excludes medicines and diagnostic services and notes state-related variation. A low treatment figure elsewhere on the page is another line, not the complete membership-plus-medicine bill.
Ivím’s homepage lists membership at $75 per month with the first month free, describing provider visits, coaches and a patient-experience team. That membership record does not provide a universal medication quote. The cost guide helps keep those two care prices from becoming an unsupported all-inclusive comparison. A first-month membership promotion is also distinct from the normal recurring cost of the selected care relationship.
The continuing-care descriptions have substance
Mochi describes access to a medical provider, nutrition and wellness support, coaching and care-team messages. Ivím emphasizes a matched provider, unlimited visits and functional health coaching. These are concrete advertised service features and can be useful reasons to understand a program beyond its product menu.
The features still require precise roles. A coach, prescribing professional and account-support team do not necessarily answer the same question. No appointment or message was tested for this comparison. The contact guide explains the distinction without inferring an observed response standard.
The outcome labels should stay attached
Mochi’s 16% first-year illustration is described as average weight loss self-reported by members, for illustrative purposes, with individual variation. It is not a randomized trial prediction for every person or a direct comparison against Ivím. The page’s calculator cannot establish an individual result.
Ivím identifies retrospective observational studies in Obesity Pillars involving branded and compounded semaglutide and tirzepatide, explicitly saying they were not randomized controlled trials. Publication and peer review are meaningful features, but they do not remove every observational limitation or prove superiority over another service.
Compare the selected relationship, not the headline
Mochi describes compounded and other treatment paths and states that compounded medicines are not FDA-approved. Ivím’s study description also spans different formulations. The selected prescription’s identity therefore needs to remain explicit, rather than being inferred from the membership or a pooled program result.
The Mochi review and Ivím review hold those details in context. Read them alongside the treatment guide and conversation guide. The comparison can clarify price, access and evidence without deciding eligibility or forecasting a personal outcome.
Use the offer details
Open the CoreAge Rx review, GLP-1 program index, and cost table to continue your comparison. Medical suitability should be discussed with a licensed clinician.
Documents used
Official public information reviewed October 1, 2026. Advertising describes an offer; it is not independent verification of treatment outcomes.